Patent ID: 9295669
Filing Date: 2016-03-29
CPC Classification: A61K,A61P

Claim Text:
1. A method of treating a patient suffering from a proliferative disorder, comprising administering to the patient: (A) a first component which comprises, as an active agent, propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]amide}, or a pharmaceutically acceptable salt thereof; and (B) a second component which comprises, as an active agent, peginterferon alfa-2a; wherein said propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]amide} is administered in an amount of from about 1700 mg/day to about 2100 mg/day, wherein said amount is about 25 mg/kg, and said peginterferon alfa-2a is administered in an amount of from about 180 μg/week to about 630 μg/week, and wherein said proliferative disorder is selected from the group consisting of: colorectal cancer, melanoma, and thyroid cancer, wherein said cancer involves a tumor comprising b-Raf having the V600E mutation.